The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
BH3 profiling as a predictive biomarker for response to cytarabine-based treatment of acute myelogenous leukemia.
William E. Pierceall
Employment or Leadership Position - Eutropics Pharmaceuticals
Stock Ownership - Eutropics Pharmaceuticals
Nicole E. Carlson
Employment or Leadership Position - Eutropics Pharmaceuticals
Stock Ownership - Eutropics Pharmaceuticals
David J. Richard
Employment or Leadership Position - Eutropics Pharmaceuticals
Stock Ownership - Eutropics Pharmaceuticals
Xuelin Huang
No relevant relationships to disclose
Michael Elaschoff
Consultant or Advisory Role - Eutropics Pharmaceuticals
Marina Konopleva
No relevant relationships to disclose
Steven Mitchell Kornblau
No relevant relationships to disclose
Michael H. Cardone
Employment or Leadership Position - Eutropics Pharmaceuticals
Stock Ownership - Eutropics Pharmaceuticals
Michael Andreeff
Consultant or Advisory Role - Eutropics Pharmaceuticals (U)